Anti-Cancer Agents in Medicinal Chemistry

Scope & Guideline

Pioneering research in medicinal chemistry for cancer treatment.

Introduction

Welcome to your portal for understanding Anti-Cancer Agents in Medicinal Chemistry, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1871-5206
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationANTI-CANCER AGENT ME / Anti-Cancer Agents Med. Chem.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

The journal 'Anti-Cancer Agents in Medicinal Chemistry' focuses on the discovery and development of novel therapeutic agents for cancer treatment. It encompasses a wide range of research areas including drug design, synthesis, and evaluation of anticancer compounds, particularly those derived from natural products and synthetic methodologies.
  1. Natural Product Research:
    The journal publishes studies that explore the anticancer properties of compounds derived from natural sources, including plants and marine organisms, emphasizing their mechanisms of action.
  2. Synthetic Chemistry and Drug Development:
    Research focusing on the design and synthesis of novel chemical entities that exhibit anticancer activity, including structure-activity relationship studies and pharmacological evaluations.
  3. Nanotechnology in Cancer Therapy:
    Articles on the application of nanotechnology for drug delivery systems, enhancing the efficacy and specificity of anticancer agents.
  4. Molecular Mechanisms of Cancer:
    Investigations into the molecular pathways and mechanisms by which various agents exert their anticancer effects, including studies on apoptosis, cell cycle regulation, and signaling pathways.
  5. Translational Research:
    Research that bridges laboratory findings with clinical applications, including studies on drug repositioning, clinical trials, and patient outcomes related to new therapeutic agents.
The journal reflects a dynamic landscape in cancer research, with several emerging themes gaining traction in recent publications. These trends indicate a shift towards innovative approaches and new therapeutic modalities.
  1. Combination Therapies:
    There is a growing interest in the synergistic effects of combining different therapeutic agents, including traditional drugs with novel compounds, to enhance treatment outcomes.
  2. Immunotherapy and Targeted Therapy:
    Research focusing on immunotherapeutic approaches and targeted therapies is on the rise, reflecting a broader trend in oncology towards personalized medicine.
  3. Molecular Docking and Computational Studies:
    The integration of computational methods in drug design and discovery is increasingly prevalent, enabling more efficient identification of promising anticancer agents.
  4. Focus on Drug Resistance Mechanisms:
    Emerging studies are increasingly addressing the mechanisms of drug resistance in cancer, aiming to develop strategies to overcome these challenges.
  5. Plant-Derived Compounds and Phytochemicals:
    There is a notable increase in research exploring the anticancer potential of phytochemicals and plant-derived compounds, highlighting their importance in drug discovery.

Declining or Waning

While the journal has maintained a strong focus on various aspects of cancer treatment, certain themes appear to be declining in prominence based on the recent publication trends. These areas may be undergoing shifts in research attention or facing challenges in innovation.
  1. Traditional Chemotherapy Agents:
    Research focused on conventional chemotherapy agents appears to be waning, with a noticeable shift toward exploring novel compounds and alternative therapies.
  2. Single-Agent Therapies:
    There is a declining emphasis on studies involving single-agent therapies, as the field moves towards combination therapies that enhance efficacy and reduce resistance.
  3. Mechanistic Studies on Established Drugs:
    The exploration of mechanisms of action for well-established anticancer drugs is less frequent, suggesting a pivot towards novel compounds and innovative therapeutic strategies.

Similar Journals

CURRENT MEDICINAL CHEMISTRY

Exploring Innovations in Drug Design and Discovery.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

Future Medicinal Chemistry

Transforming challenges into opportunities in drug development.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

RSC Medicinal Chemistry

Innovative Research for Tomorrow's Therapeutics
Publisher: ROYAL SOC CHEMISTRYISSN: Frequency: 12 issues/year

RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Connecting Ideas, Enhancing Therapies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Recent Patents on Anti-Cancer Drug Discovery

Unlocking Innovations in Anti-Cancer Drug Discovery
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

BIOORGANIC CHEMISTRY

Advancing the frontiers of biochemistry and organic chemistry.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0045-2068Frequency: 12 issues/year

BIOORGANIC CHEMISTRY, published by Academic Press Inc., a prestigious imprint of Elsevier Science, represents a cornerstone in the fields of biochemistry, organic chemistry, and drug discovery. With an impressive Scopus rank placing it in the top quartiles across critical categories—including Q2 for Biochemistry and Drug Discovery, and Q1 for Organic Chemistry—this journal has established itself as a vital resource for researchers, professionals, and students alike. Featuring a diverse array of articles that explore innovative methodologies and emerging trends from 1971 to the present, BIOORGANIC CHEMISTRY effectively bridges the gap between laboratory research and practical applications. Although not an Open Access journal, its rigorous peer-review process ensures the delivery of high-quality, impactful research that drives advances in the understanding and application of biochemistry. With an aim to facilitate scientific discourse and collaboration, it invites contributions that further the exploration of chemical processes within biological systems.

Iranian Journal of Pharmaceutical Research

Championing excellence in pharmacological research and discovery.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

TETRAHEDRON LETTERS

Elevating Chemical Research to New Heights
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0040-4039Frequency: 52 issues/year

TETRAHEDRON LETTERS, published by Pergamon-Elsevier Science Ltd, is a leading journal in the fields of Biochemistry, Drug Discovery, and Organic Chemistry, with a rich legacy since its inception in 1959. This prestigious journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of chemical sciences, featuring high-impact research that influences both academic and practical applications. Although it is currently classified in the third quartile across its categories for 2023, its rigorous peer-review process ensures the publication of quality research that contributes to the scientific community. With an ISSN of 0040-4039 and an E-ISSN of 1873-3581, TETRAHEDRON LETTERS is easily accessible for those in the academic landscape seeking to stay abreast of innovative developments. Researchers, professionals, and students alike will find invaluable insights and collaborative opportunities within the pages of TETRAHEDRON LETTERS, making it an essential read for anyone involved in the chemical sciences.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Empowering Researchers with Peer-Reviewed Excellence
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

CHEMISTRY LETTERS

Innovative insights for the chemistry community.
Publisher: CHEMICAL SOC JAPANISSN: 0366-7022Frequency: 12 issues/year

Chemistry Letters, published by the Chemical Society of Japan, is a distinguished academic journal that focuses on pivotal developments in the field of chemistry. Since its inception in 1973, the journal has been a vital platform for the dissemination of novel research findings across various sub-disciplines, encompassing both theoretical advancements and practical applications. As a testament to its significance in the community, Chemistry Letters has achieved a Category Quartile of Q2 in the 2023 ranking for miscellaneous Chemistry journals, reflecting its respected position among peers. Although it does not offer Open Access, the journal remains accessible through institutional subscriptions, thus ensuring a wide reach for its valuable content. With an active scope ranging from general chemistry topics to specialized studies, it is ideal for researchers, professionals, and students alike who seek to contribute to and expand their knowledge within this dynamic field. The journal continuously aims to promote excellence in chemical research, facilitating dialogue and collaboration among chemists worldwide.